[San Diego (U.S.) = E-Daily Reporter SONG YOUNG-DOO ] “Our forecast for 15–20% growth by year-end remains unchanged. Our growth strategy and plans have not changed either. We will steadfastly continue the three-pillar expansion strategy—production capacity, portfolio, and global hubs—that SAMSUNG BIOLOGICS has been consistently pursuing.”

John Lim, CEO of SAMSUNG BIOLOGICS, made these remarks while reaffirming this year’s growth guidance at a press conference held during the 2026 BIO International Convention (BIO USA) in San Diego, USA.

The most significant change compared to last year is the acquisition of the Rockville, U.S., production facility. SAMSUNG BIOLOGICS(207940)completed the acquisition of the Rockville plant in late March, further strengthening its global production footprint. CEO John Lim said, “The Rockville acquisition was an excellent decision,” adding, “520 local employees have joined SAMSUNG BIOLOGICS and are now working with us.”

However, he explained that U.S. production also presents practical challenges, such as cost burdens. “Production costs in the U.S. are about twice those in Korea,” he said. “Since the Rockville plant was originally designed for a specific client, some modifications are needed to accommodate a diverse range of clients; however, we determined that these challenges were manageable, which is why we decided to proceed with the acquisition.”

Decision on Plant 6 to Be Made This Year… 1.325 Million Liter Capacity to Be Established in Songdo by 2032

Expansion of domestic production capacity is also proceeding as planned. CEO John Lim stated, “We are continuing to receive orders for Plant 5, and we plan to decide on the construction of Plant 6 within this year,” adding, “We are reviewing the application of a standard 180,000-liter design for Plants 6, 7, and 8.”

He continued, “Adopting 180,000 liters as the standard concept will enhance design and operational efficiency,” adding, “In the U.S. as well, we are considering this approach following the Rockville facility.”

SAMSUNG BIOLOGICS plans to complete its Second Bio Campus (Plants 5–8) by 2032, establishing a total production capacity of 1,325,000 liters in Songdo. Including the Rockville plant, total global production capacity will expand to 1,385,000 liters.

The final direction for the much-anticipated Bio Campus 3 has not yet been finalized. However, the company explained that it is actively considering the peptide sector to differentiate it from its existing antibody-focused production facilities.

CEO John Lim stated, “While Campuses 1 and 2 are antibody-focused, we are looking at peptides—particularly the GLP-1 sector—for Campus 3,” adding, “As many companies are developing obesity treatments, we are also reviewing the associated production demand.”

He continued, “We are also looking into AAV (aden-associated virus), cell and gene therapies (CGT), and other areas besides GLP-1, but we consider these to be nascent markets at this stage,” explaining, “As things stand, it is relatively more likely that we will move into the peptide or small antibody sectors.”

He also maintained an optimistic outlook on the antibody drug market. “The antibody market is still growing at an annual rate of over 10%, and I do not view it as an oversupplied market,” he said. “As the market evolves from monoclonal antibodies to bispecific and multispecific antibodies, the required production volume is actually increasing, and the range of applications is also continuously expanding.”

European Sales Hub in the Netherlands… “Strengthening Competitiveness in Global Order Acquisition”

As part of its strategy to expand its global footprint, the company is also accelerating its entry into the European market. SAMSUNG BIOLOGICS plans to open a European sales office in the Netherlands in the third quarter of this year.

CEO John Lim explained, “The Netherlands is located in the heart of Europe, offers excellent accessibility, and is a cost-competitive region,” adding, “We determined that its proximity to the airport makes it an ideal sales hub for supporting clients across Europe.”

With this move, SAMSUNG BIOLOGICS will secure a sales hub in Europe—following those in New Jersey, U.S., and Tokyo, Japan—thereby establishing a network that spans major global biopharmaceutical markets.

He also expressed confidence in the company’s ability to secure new orders. “I previously mentioned that we had secured the top 17 global pharmaceutical companies by market capitalization as clients, but that number is likely even higher now,” he said. “As mergers and acquisitions (M&A) in the biotech industry are actively taking place, our client base is naturally expanding.”

Full-Scale Open Innovation with Lilly… Expanding Investment

in

Next-Generation Technologies

SAMSUNG BIOLOGICS is also

expanding its investment

in

next-generation

biotechnology through its Life Sciences Fund. Following its first fund (1700억 원) and second fund (720억 원), the company recently established a third fund worth 2000억 원, thereby strengthening its investment capacity.

The company is continuously evaluating various next-generation modalities, including AAV, mRNA, ADCs (antibody-drug conjugates), and biomarkers.

CEO John Lim stated, “We plan to expand our investments in next-generation biotech even more aggressively,” adding, “We will continue to expand our global network and business opportunities while collaborating closely with our portfolio companies.”

Open innovation collaboration with Eli Lilly is also set to begin in earnest. He explained, “The open innovation space we are developing with Lilly will be located on Campus 2 and is scheduled to open in July,” adding, “About 30 companies are expected to move in, and we plan to actively consider investing in promising companies among them.”